HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Nexxus and Tresemme fueled a 9.2% increase in global consumer products sales to $360 mil. during the third quarter (ended June 30), and earnings before income taxes for the unit advanced 9.2% to $32.6 mil., Alberto announces July 27. The beauty supply business, which includes Sally Beauty and Beauty Systems Group, had sales of $599.5 mil., representing growth of 4%, while earnings before income taxes for the division were up 8.6% to $65.5 mil. Alberto's net sales in Q3 increased 6% to $952.7 mil. Due to a $50 mil. termination fee associated with the failed merger of Alberto's beauty supply business with Regis Corporation, Alberto's net earnings plummeted 42.9% to $30.5 mil., including non-core items. Alberto recently announced it will spin off Sally as a separate entity in a transaction expected to close in December (1"The Rose Sheet" June 26, 2006, p. 3)...

You may also be interested in...

Alberto-Culver Eyes Acquisitions Following Sally Spin-Off

Alberto-Culver's consumer products division will make acquisitions a top priority following the spin-off of Sally Beauty Company, the firm stated during a June 19 call announcing the decision

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.



Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts